A Massive Market Trend Is Forming in Psychoactive Drug Therapies!


Emerging biotechs are researching once forbidden drugs to solve some of the most vexing medical problems...those of mental health.

Major investors have launched this sector with over a half-billion dollars in start-up capitalization and they’re already seeing substantial returns!

This trend is just getting started!

Forbes
 reports that the emerging market in new psychoactive mental health medications... “could bring in a whopping $6.85 billion by 2027.”
 






CNBC: Investors Are Going Big in Psychoactive Drug Breakthroughs1

New report finds that since COVID-19 pandemic hit, nearly half of U.S. workers suffer from mental health issues.2 This crisis launched a massive new sector in mental health therapies... and it’s rapidly soaring to a multi-billion market size!

It’s an entirely new world as government, military and medical researchers aggressively pursue newly discovered potential in previously ignored psychoactive compounds. These future wonder drugs are now showing enormous potential for the treatment of mental disorders and even brain injury.

This report focuses on the investment opportunities now taking shape in this rapidly evolving market. You’ll learn how the trend got started, some of the major players behind it, and most important, how you can get involved now.



Please don’t set this aside. This is one of the most important and fastest moving trends in the market today.

 
We are Now Entering Phase Two of a Pharmaceutical Renaissance
 
Research is mounting. An entirely new class of psychoactive medications is showing profound efficacy in treating mental disorders and traumatic brain injuries.

This is cutting edge medical science that has been buried for decades by out-of-date taboos. But times are changing.

 
Findings are that once-forbidden psycho-active compounds now being extracted from organic sources hold significant promise for treating, even curing mental disorders and injuries once thought to be incurable.

Legal restrictions formerly kept these compounds out of the lab, their benefits remained clouded in secrecy. Now those secrets are coming to light and it appears clear to many that was a HUGE missed opportunity.

My calculations reveal the market for psychoactive medicines and drug therapies could accelerate many times faster than what investors anticipated from the cannabis market.

This projected market growth can be expected to drive innovative, start-up biotech companies to rapid growth over the coming months. Some early starters have already achieved significant growth as eager investors rushed to establish ground floor positions.

What’s compelling is that those ground-floor positions have been launched by high-net-worth investors that now fuel the trajectory of this soaring market trend.

One new company, MINDCURE (OTC: MCURF | CSE: MCUR), recently began public trading and after being launched raised a whopping C$26.6 million in start-up capitalization! This funding pattern can be found behind many new companies pursuing break-throughs in psychoactives.

High-net-worth investors, like Kevin O’Leary of Shark Tank fame, are investing millions into the sector... and it’s not just for altruistic reasons. Their intention is to profit enormously from a market that starting from virtually nothing today, yet is now projected by some to reach a $6.85 billion market size through the year 2027.6

Their efforts have already paid off... and will likely continue. Last year, Kevin O’Leary dove into MindMed with millions in pre-IPO funding and today... let him tell it like it is:
 

Money is quite literally pouring in. On January 7, 2021, the company announced a new round of funding that “bolstered” its available Cash on Hand to US $144.4 million!8 The announcement was made under a headline confirming “High Investor Demand”. Indeed.

This has become a $2 billion market cap company! Just last August it was trading at around 34¢! Now its ranging around $4.00!

Early investors got a great start and as the company Co-CEO, J.R. Rahn, put it:

“We were the first... and now... the space is moving very, very quickly.”9

How quickly is it moving? It’s absolutely rocking!


MINDCURE, which will be discussed throughout this report, has just recently gone public with its own initial round of financing now totaling C$26.6 million through early February.6

For reference, MindMed announced an early October funding of $28.75 million, which lifted its funding to $37.8 million total.10 It has since grown to nearly four-times that amount!11

Launches in this space are setting records!

At present, only a handful of companies have entered the space. Some of the early entries, like MindMed, have seen exceptional returns for early investors.

Three that have been on our radar prior to finding MINDCURE posted gains that we rarely see in any market.

Starting out with C$26.6 million in start-up funding, MINDCURE is firmly on a well funded opening track.

Judging by the rapid success of predecessors, I believe investors seeking early opportunities in this rapidly evolving market trend could do very well by evaluating MINDCURE while it remains in a ground floor position.


 
    

MINDCURE has a unique story to tell that greatly increases its prospects for rapid growth in psychoactive medications.

As was made clear by the MindMed record, fund-raising is key to success. MINDCURE appears to be running along the same track as it attracts millions in new funding. The driver behind those raises is Kelsey Ramsden, the company CEO who was named Canada’s Top Female Entrepreneur for two years running.

Ms. Ramsden is well known in Canada and the United States for having built multiple, multimillion-dollar businesses both offline and online. No question, she knows people and how to pitch a business! She serves as a Mentor on the Richard Branson Centre for Entrepreneurship and was recognized as one of the Ernst & Young Entrepreneurial Winning Women. She was one of two Canadian entrepreneurs recognized for this award. She became part of Dell Women’s Entrepreneur Network in March 2014 and is now ranked among the top 200 women entrepreneur’s globally.12,13

Ramsden’s connections and reputation add up to one essential thing... she’s got some serious people who will answer her call. More important, there are well-heeled investors who have backed her ventures with millions in new money.

Landing C$26.6 million in equity funding speaks volumes to both her skills and prospects for the company that she is leading. It says a lot about the significance of the work being done at MINDCURE.

Ramsden’s success in raising millions in investment capital is a direct result of the world-class team of researchers and scientists assembled at MINDCURE. These are the people driving the success of the company... and importantly, attracting future investor interest so that R&D can be well financed through the start-up years.








 



 

DR. RYAN HARTWELL, PHD
Chief Science Officer


Dr. Hartwell, an entrepreneur with a strong record of successful business startups, is a co-inventor of FS2 and AI-001 cell therapy. Prior to undertaking his PhD, he cofounded ATS Biotech Inc., an advanced, biomedical wound care company specializing in the development and manufacture of medical devices. He has published 20 peer-reviewed articles, 26 presentation abstracts, and holds four patents. Dr. Hartwell graduated with honors in Biochemistry from the University of Ottawa and received his PhD in Experimental Medicine at UBC. He received the Vancouver Coastal Health Research Institute Award for Top Graduating Doctoral Student and Rising Star in Research.

GEOFF BELAIR
Chief Technology Officer

Geoff has decades of experience in computer technology and systems analysis. At MINDCURE, he has been instrumental in building out the iSTRYMTM and PsyCollageTM technology platforms. Management anticipates that these platforms can be significant revenue generators in the years ahead. He recently released his first novel, Time Station, which details the professional life of a forensic technologist whose job is to track down evidence left behind after hackers attack a company’s computer systems. He has spent thirty-nine years as a technician, systems architect, and programmer designing large transactional systems primarily focused on the specialized needs of financial institutions.

 
MINDCURE intends to become a significant player in the evolution of this mental health renaissance.

The company intends to focus its R&D on key areas of science that remain open to further investigation and therapeutic development.


Progress has already been made with novel utilization of psychoactive pharmaceutical therapies targeting the five key areas described above. All have passed through or advanced in the “lead optimization” phase preceding phase one clinical trials.
 
Additionally, MINDCURE research in these areas has opened pathways to “New Molecular Entities” (NMEs), which are proprietary products of R&D and subject to future patents and licensing.

Treatment Resistant Depression. This refers to a condition where patients fail to gain satisfactory benefit from currently prescribed anti-depressant medications or psychological therapies. This is a serious problem affecting around one-third14 of patients diagnosed with depressive disorders. The National Institute of Health reports that thirty percent of patients with treatment-resistant depression (TRD) attempt suicide at least once during their lifetime.15

MINDCURE has been advancing its R&D into psychoactive medications that augment or replace existing drug therapies to effect complete remission of depressive disorders.

Neuropathic Pain. This kind of pain is triggered by damage to nerves, the brain, brainstem, or spinal cord. Typical therapeutic protocols are to suppress the pain with medications, the most powerful being opioids. These protocols do not address the underlying cause of the pain. MINDCURE is developing psychoactive drug therapies that can address the underlying causes to repair damage or reroute neuropathways and, in a manner of speaking, shut down damaged nerve tissues.

Cluster Headache. The Mayo Clinic reports that cluster headaches “... are one of the most painful types of headache”16 and can last from weeks to months.” MINDCURE is developing novel approaches in drug therapies that rather than suppressing symptoms, target the region of the brain that triggers the headaches.

Migraine. WebMD reports that, “Doctors aren’t totally sure what causes migraine headaches, but they think imbalances in certain brain chemicals may play a role.”17 Those imbalances can be attributed to dysfunctions of the trigeminal nerve that trigger such imbalances in neurotransmitters to cause intense pain. MINDCURE research shows great promise in preventing the neuropathic origins of migraine pain.

Traumatic Brain Injury (TBI). Traumatic brain injury can present in a variety of ways, the most common being concussions.
 
The CDC describes TBI as “... a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury.”18 Damaged nerves are largely believed to be incurable. However, MINDCURE is uncovering great promise in the curative potential of certain psychoactive compounds that actually promote nerve healing and recovery.

Ongoing research both within MINDCURE and outside has accumulated significant evidence of successful psychoactive drug therapies for all five of these research priorities.

Currently, MINDCURE’s R&D efforts are particularly focused on the potential for psychoactive compounds in the treatment of migraine and traumatic brain injury.


The pressing need of migraine sufferers poses a huge opportunity for MINDCURE’s breakthrough treatments. It’s an affliction that in the U.S. alone accounts for $40+ billion in direct medical and lost productivity costs.19
 
Long standing approaches to migraine management have been suppression of pain. MINDCURE’s approach could be revolutionary. The company reports that it is pursuing a discovery track to correct the underlying physiological causes of migraine headaches. This could cure the ailment, not just cover it up.

The long-term pharmaceutical value of a psychoactive therapy for the treatment and potential cure of migraines could be worth billions.20 And it doesn’t end there.

Similar mechanisms of action in psychoactive medications are proving effective in the restoration and repair of neural pathways, a Holy Grail of medical breakthroughs. Specifically, MINDCURE is seeking pharmaceutical advances that can lead to healing traumatic brain injuries, aka concussions.

Until now, there has been no known cure for a traumatic brain injury. MINDCURE intends to advance the newly discovered therapeutic value of psychoactives toward long awaited treatments.

The need for solutions is simply enormous.

According to the most recent data (2014) reported by the CDC, “Each year, TBI causes a substantial number of deaths and leads to life-long disability for many Americans. In fact, TBIs contribute to about 30% of all injury deaths in the United States. In 2014, there were:
 
  • Approximately 2.5 million TBI-related emergency department visits,
  • Approximately than 288,000 hospitalizations, and
  • Nearly 57,000 deaths related to TBI.”21

The impact of a traumatic brain injury varies widely as a function of the severity of the injury. A mild TBI typically presents short-term symptoms. The patient can feel better within a few days or weeks.

However, individuals suffering a moderate or severe TBI may be impacted long-term, perhaps even for life as a result of the injuries.
 
What MINDCURE is pursuing are completely new and transformative approaches to curing mental illness and brain injury.

This approach is starkly different from the prevailing protocols that target symptoms with little impact on the underlying causes.

MINDCURE is aggressively pursuing the psychoactive compounds that can repair and potentially heal the malfunctioning neuropathways.

From their discoveries, the company seeks to advance medical knowledge of new curative protocols and in so doing, advance the development of proprietary “New Molecular Entities” that can be patented and advanced through FDA trials to pharmaceutical approval and subsequent commercialization.

In its goal to proprietary NMEs and advancement to FDA approval, MINDCURE developed unique, proprietary technologies that could greatly accelerate the approval processes and dramatically reduce costs.
 
MINDCURE R&D technologies could become essential tools for biotech R&D worldwide. This opens the way to significant potential in intellectual property (IP) licensing revenue.

MINDCURE launched its R&D programs with a stellar team of scientists and medical researchers. In conjunction with the medical side, the company also engineered two proprietary software platforms that perform distinctly different, important functions.

Mental illness and injury present in many different symptoms, often either subjective or transient, which makes them either difficult to quantify or to catch at the right moment.

To overcome the challenges of gathering timely, empirical patient data, MINDCURE developed and launched iSTRYMTM, a proprietary Digital Therapeutics DataBase Platform that tracks and records vital patient information during mental health evaluation, diagnosis and treatment.

The company reports that, “iSTRYM is designed to provide close to real-time data regarding patient care, procedures and protocols, and other resources for therapists, clinicians and patients with mental health concerns. iSTRYM has been designed to act as a centralized management system for therapeutic insights, the deployment of care and integration based on a microservices design model, and is being built with responsive principals.”

On a parallel path, MINDCURE developed PsyCollageTM, a research and development platform that employs statistical and predictive analytics to guide the company’s research and development decisions. PsyCollage more efficiently advances discovery processes so less time and money is spent pursing nonproductive research. The net effect is that development of proprietary and patentable New Molecular Entities moves more efficiently to end stages.
 
The prospect of future technology licensing adds significant potential for future company revenues and shareholder value.

The combination of iSTRYM and PsyCollage technology could revolutionize how neurological drug candidates can be accelerated through FDA processes. The FDA’s rigorous proof standards rely heavily on hard data points. iSTRYM and PsyCollage promise to provide more of that essential data.

Don’t be caught napping. You can see from the stock charts above that the trend in this sector is triggering stunning and rapid upside moves. Now is the ideal time to seek a ground floor position.

For the moment, very few investors are even aware of what lies ahead. MINDCURE is positioned for significant growth in shareholder value. This is the ideal time to evaluate MINDCURE for your growth portfolio.


 

MINDCURE R&D technologies could become essential tools for biotech R&D worldwide. This opens the way to significant potential in intellectual property (IP) licensing revenue.

Now Is an Ideal Time to Consider
the Investment Potential in
MINDCURE Health
 
You’re witnessing a fast evolving market propelling significant change in therapeutic approaches to mental health conditions.
 
Investors should move quickly to evaluate this opportunity.

Long gone are the days when psychoactive compounds were shunned to dark markets. Widespread legalization of medical marijuana flung the door open to radical new thinking about psychoactive compounds and their pharmacological efficacy. It’s time to follow the science and the market impact, now strongly driven by these powerful forces.

Hundreds of millions of dollars have been invested by Silicon Valley and Wall Street billionaires. This sector is gaining traction from a virtual standstill to a $6.85 billion market over the next six years. This market appears on the threshold of rocketing gains and it’s just now getting started.

The US military has so far committed $25 million into R&D for using psychoactive compounds in the treatment of PTSD. Clinical studies are suggesting that significant benefit can be achieved through therapeutic administration of psychoactive compounds.

The FDA has fast tracked approvals for new psychoactive drug discoveries. This comes as jurisdictions in Canada and the United States have begun lifting the decades-old restrictions that prevented psychoactive compounds from being considered for pharmaceutical use.

University and private research facilities, such as John Hopkins, have moved aggressively to uncover the pharmaceutical value of psychoactive compounds. Their work is being funded by millions in new grants now flowing from multiple sources.

MINDCURE’s progress toward new, psychoactive pharmaceuticals targeting migraines and brain injury could be permanently transformative to patients suffering from these difficult-to-treat medical conditions. It stands out as one of the most important directions in this trend.

MINDCURE also pioneered new technologies that promise to greatly improve the speed and efficiency of discovering and advancing new drugs to market. The company’s proprietary iSTRYMTM Digital Therapeutics DataBase and PsyCollageTM statistical and predictive analytics hold potential for becoming major revenue generators to the company as these technologies become licensable to research facilities worldwide.
 
MINDCURE targets immediate, near-term revenue potential as the nootropics market projects to triple in size over the next two years.
 
The entire industry is now soaring from US $1.96 billion to just shy of $6 billion over the coming two years.24

 
 



NOOTROPIC: A drug or dietary supplement used to enhance memory and other high-level cognitive functions as well as general wellness. Recent discoveries of trace compounds found in the lion’s mane mushroom have been shown to improve mental health and increase productivity in patients taking lion’s mane as a dietary supplement.
 
Nootropics are typically naturally-derived compounds reported to enhance cognitive performance. These compounds, when consumed as a dietary supplement, “... can boost the memory, enhance creativity levels, decision making capabilities and improve brain performance.”25

Nootropic medications are available in both prescription and non-prescription form. In testimony to their effectiveness, prescription versions can be used to counteract the symptoms of attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease, or narcolepsy. The nonprescription versions target more generalized areas of cognitive performance, such as boosting mental performance, memory, and executive functions.
 
What to do now...

MINDCURE’s rapid progress toward new treatments and cures for migraines and brain injury could prove permanently transformative to diagnosing and treating these afflictions. Further, the technological promise of the company’s proprietary iSTRYM data tracking system and PsyCollage technology could become a common tool licensed to research facilities worldwide.

Recommended next steps:
  1. Start your due diligence now. Go to: https://mindcure.com/. Be sure to register your email address for company updates and future news releases.
  2. Go to your broker and add MINDCURE (CSE: MCUR / OTC: MCURF) to your stock watch list. Please note, MINDCURE has only recently begun public trading. Now is the time to consider initiating a position while it trades at start-up levels.
  3. Familiarize yourself with how this new class of medical psychoactive compounds is revolutionizing pharmacology. These are rapidly evolving trends that could have a profound impact on mental health...and it’s gaining traction fast!

 

Source: 

1 https://maps.org/news/media/7677-cnbc-investors-are-starting-to-bet-big-on-psychedelic-medicine
2 https://www.cnbc.com/2021/02/10/half-of-us-workers-suffer-mental-health-issues-since-covid-19-hit.html
3 https://www.forbes.com/sites/irisdorbian/2021/01/21/why-investors-are-bullish-about-psychedelics/?sh=791eb9c31a41
4 https://www.hopkinsmedicine.org/psychiatry/research/psychedelics-research.html#:~:text=Psychedelics%20Research% 20and%20Psilocybin%20Therapy.%20The%20Johns%20Hopkins,and%20its%20potential%20as%20therapeutics%20for%20mental
5 https://maps.org/news/media/7677-cnbc-investors-are-starting-to-bet-big-on-psychedelic-medicine
6 https://www.forbes.com/sites/irisdorbian/2021/01/21/why-investors-are-bullish-about-psychedelics/?sh=791eb9c31a41
7 https://www.fool.com/investing/2021/01/06/mind-medicine-why-kevin-oleary- thinks-this-psyched/#:~:text=Shark%20Tank%20star%20Kevin%20O’Leary%20has%20 invested%20in,company%20Mind%20Medicine%20(OTC:MMED.F),%20also%20 known%20as%20MindMed.
8 https://mindmed.co/news/press-release/mindmed-closes-upsized-financing-of-cad-92-1m-usd-72-7m-to-meet-high-investor-demand/
9 https://finance.yahoo.com/video/space-moving-very-quickly-mindmed-201014893.html
10 https://mindmed.co/news/press-release/mindmed-closes-upsized- financing-of-cad-28-75m-with-strong-institutional-demand-for-psychedelic-medicines/
11 $144.4 / $37.8 Cash on Hand totals as reported by Mind Med
12 https://en.wikipedia.org/wiki/Kelsey_Ramsden
13 https://www.nsb.com/speakers/kelsey-ramsden/
14 https://psychedelicspotlight.com/peter-thiel-invests-12-million-in-psychedelic-drug-manufacturer/
15 https://pubmed.ncbi.nlm.nih.gov/29665520/#:~:text=Treatment-resistant%20
16 https://www.mayoclinic.org/diseases-conditions/cluster-headache/symptoms-causes/ syc-20352080
17 https://www.webmd.com/migraines-headaches/migraines-causes
18 https://www.cdc.gov/traumaticbraininjury/index.html
19 https://www.medgadget.com/2021/01/alzheimers-therapeutics-market-to-reach-usd-13-57-billion-by-2027-size-share-industry-analysis-and-global-forecast-to-2027.html
20 https://www.forbes.com/sites/irisdorbian/2021/01/21/why-investors-are-bullish-about-psychedelics/?sh=40d80d1b1a41
21 https://www.cdc.gov/traumaticbraininjury/severe.html
22 https://www.cnbc.com/2021/02/10/half-of-us-workers-suffer-mental-health-issues-since-covid-19-hit.html
24 https://www.globenewswire.com/news-release/2019/01/11/1690384/0/en/Global-Nootropics-Market- Will-Reach-USD-5-959-Million-By-2024-Zion-Market-Research.html
25 https://www.globenewswire.com/news-release/2020/02/19/1987135/0/en/Nootropics-Market-To- Reach-USD-5-32-Billion-By-2026-Reports-And-Data.html
26 https://psychedelicspotlight.com/peter-thiel-invests-12-million-in-psychedelic-drug-manufacturer/
27 https://www.brainyquote.com/quotes/peter_thiel_425644#:~:text=-%20Peter%20Thiel%20quotes%20
28 https://en.wikipedia.org/wiki/Peter_Thiel
29 https://www.brainyquote.com/quotes/peter_thiel_425644#:~:text=-%20Peter%20Thiel%20quotes%20

THIS PUBLICATION IS AN ISSUER-PAID ADVERTISEMENT. This paid advertisement includes a stock profile of Mind Cure Health Inc. (“Mind Cure”) (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH). To enhance public awareness of Mind Cure its securities, the issuer has agreed to pay Sandstone Media Inc. (“Sandstone”) US$1,960,632 to provide a broad range of product and brand awareness, marketing and media services, Sandstone has subsequently agreed to pay Moskowitz $25,000 dollars ($) in cash from the amount it has received from Mind Cure. The Moskowitz Report is an investment newsletter which is also being advertised herein. As a result of this advertisement, Moskowitz may also receive subscription and advertising revenue from new subscribers. As of the date these materials are disseminated, neither Sandstone nor Moskowitz currently hold the securities of Mind Cure and none intends to purchase such securities for a period of ninety (90) days following the end of this advertising campaign. This advertisement may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Mind Cure, increased trading volume, and possibly an increased share price of Mind Cure’s securities, which may or may not be temporary and decrease once the advertising campaign has ended. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. None of Sandstone, Moskowitz or any of their respective owners or employees is registered as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), or any state or provincial securities regulatory authority, or any self-regulatory organization. FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This publication is for educational and informational purposes only. This publication is based exclusively on information generally available to the public, which public information is believed to be reliable and accurate but are subject to the risk and assumptions contained in such disclosure. Nevertheless, neither Sandstone nor Moskowitz cannot guarantee the accuracy or completeness of the information. This publication does not purport to be a complete analysis of this company’s financial position. The publication or any statements made in this publication are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this publication should NOT be relied upon for purposes of transacting in the securities mentioned in this publication, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this publication or in any other security or strategy. SUBSTANTIAL RISK INVESTMENT. Any individual who chooses to invest in the securities mentioned in this publication or any securities should do so with caution. Investing or transacting in securities, and in particular micro-cap securities such as Mind Cure, involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional. RESULTS PRESENTED ARE NOT VERIFIED OR TYPICAL; ACTUAL RESULTS WILL VARY. This publication contains information regarding historical trading performance. Please be aware that these results have not been verified or tracked, past performance is not necessarily indicative of future results, and the results presented in the publication are NOT TYPICAL, AND SHOULD NOT BE UNDERSTOOD AS TYPICAL, FOR ANY READER. Actual trading results for readers will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. The advertising agencies will retain as their compensation any excess sums after all expenses are paid. Mind Cure’s officers, directors, principals, insiders, consultants and employees may be beneficial owners of securities of Mind Cure and they have been advised of the need to abide by the trading policies of the Canadian Securities Exchange and other applicable regulation and the need to comply with reporting obligations with respect to their trading, if applicable . USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this publication may constitute forward- looking statements within the meaning of Sections 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this advertisement includes, but is not limited to, statements with respect to: trends within the industry and any potential market size or value; comparisons to results and performance of other industries or markets; areas of focus for new research and potential benefits or outcomes of such research; the involvement of U.S. military and any other person in research or related matters; the potential life changing effects of compounds and drugs and the timing thereof; the investment behavior of individuals or the market in general; the intended research of Mind Cure and any other business plans for Mind Cure or its products, including the timing thereof, potential markets and customers; possible benefits of products, and other developments or methods to commercialize its products; and anything in connection with possible future value to shareholders or the share price of Mind Cure. Although the forward-looking information contained in this advertisement is based upon what Moskowitz believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information. Forward-looking information is provided for the purpose of presenting information about Moskowitz’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the economy, Mind Cure’s industry and its business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect its investments, results of operations, financial condition and its ability to obtain additional equity or debt financing, and satisfy its financial obligations; future growth potential; competition for mental health and wellness investments and competition within the industry for products and services; Mind Cure may not develop or produce compounds, drugs or other products that help Mind Cure achieve its goals or business objectives; changes in legislation or regulations that may negatively impact Mind Cure’s business; and Mind Cure may not increase in value for its shareholders or at all. Moskowitz believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, Moskowitz can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects Moskowitz’s current beliefs and is based on public information currently available from Mind Cure. The forward-looking information is stated as of the date of this advertisement and neither Mind Cure nor Moskowitz assumes any obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law. This advertisement does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. Mind Cure’s securities have not been and will not be registered under the U.S. Securities Act of 1933 (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. TRADEMARKS AND COPYRIGHT. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. This document is subject to copyright laws of Canada and the US and may not be reproduced in any form for other than personal use without the prior written consent of the publisher. This document may be quoted in context, provided proper credit is given.